The Potential Therapeutic Effect of Melatonin in Gastro-Esophageal Reflux Disease

Phase

Condition

Gastroesophageal Reflux Disease (Gerd)

Esophageal Disorders

Heartburn (Pediatric)

Treatment

N/A

Clinical Study ID

NCT00915616

Melatonin and reflux

Ages 42-56
All Genders
Accepts Healthy Volunteers

Study Summary

Gastro-Esophageal Reflux Disease was defined as a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. Many drugs used for the treatment of GERD such as omeprazole (a proton pump inhibitor) which is widely used anti-ulcer drug and has been demonstrated to protect against esophageal mucosal injury. Melatonin has been found to protect the gastrointestinal mucosa from oxidative damage caused by reactive oxygen species in different experimental ulcer models. The aim of this study is to evaluate the role of exogenous melatonin in the treatment of reflux disease in human either alone and in combination with omeprazole therapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

patient with GERD ranged from 42 to 56 years

Exclusion

Exclusion Criteria:

patients with cardiac disease
patients with renal affection
patients with liver diseases (due to drug induced, autoimmune disease and viralhepatitis)
patients on the drugs known to affect the GIT motility (phenothiazines,anticholinergics, nitrates or calcium channel blockers) were excluded during the timeof conduction of the study or the preceding two weeks